These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20590829)

  • 1. Muscle weakness and neuromuscular junctions in aging and disease.
    Shigemoto K; Kubo S; Mori S; Yamada S; Akiyoshi T; Miyazaki T
    Geriatr Gerontol Int; 2010 Jul; 10 Suppl 1():S137-47. PubMed ID: 20590829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
    Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases.
    Punga AR; Ruegg MA
    Curr Opin Pharmacol; 2012 Jun; 12(3):340-6. PubMed ID: 22365504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age affects reciprocal cellular interactions in neuromuscular synapses following peripheral nerve injury.
    Kawabuchi M; Tan H; Wang S
    Ageing Res Rev; 2011 Jan; 10(1):43-53. PubMed ID: 20943206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
    Maruyama N; Shigemoto K
    Rinsho Shinkeigaku; 2007 Nov; 47(11):842-4. PubMed ID: 18210813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors contributing to neuromuscular impairment and sarcopenia during aging.
    Edström E; Altun M; Bergman E; Johnson H; Kullberg S; Ramírez-León V; Ulfhake B
    Physiol Behav; 2007 Sep; 92(1-2):129-35. PubMed ID: 17585972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular architecture of the neuromuscular junction.
    Hughes BW; Kusner LL; Kaminski HJ
    Muscle Nerve; 2006 Apr; 33(4):445-61. PubMed ID: 16228970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geoepidemiology of myasthenia gravis [corrected].
    Meyer A; Levy Y
    Autoimmun Rev; 2010 Mar; 9(5):A383-6. PubMed ID: 19922815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia.
    Bütikofer L; Zurlinden A; Bolliger MF; Kunz B; Sonderegger P
    FASEB J; 2011 Dec; 25(12):4378-93. PubMed ID: 21885656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of the neuromuscular junction: molecules and mechanisms.
    Meier T; Wallace BG
    Bioessays; 1998 Oct; 20(10):819-29. PubMed ID: 9819569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis of myasthenia gravis].
    Téllez Zenteno JF; Morales Buenrostro LE; Torre Delgadillo A
    Rev Invest Clin; 2000; 52(1):80-5. PubMed ID: 10818814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease.
    Balice-Gordon RJ; Smith DB; Goldman J; Cork LC; Shirley A; Cope TC; Pinter MJ
    Ann Neurol; 2000 May; 47(5):596-605. PubMed ID: 10805330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune myasthenia gravis in childhood.
    Andrews PI
    Semin Neurol; 2004 Mar; 24(1):101-10. PubMed ID: 15229797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia: prevalence, mechanisms, and functional consequences.
    Berger MJ; Doherty TJ
    Interdiscip Top Gerontol; 2010; 37():94-114. PubMed ID: 20703058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
    Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
    Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis: a personal view of pathogenesis and mechanism, part 2.
    Simpson JA
    Muscle Nerve; 1978; 1(2):151-6. PubMed ID: 220530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms Regulating Neuromuscular Junction Development and Function and Causes of Muscle Wasting.
    Tintignac LA; Brenner HR; Rüegg MA
    Physiol Rev; 2015 Jul; 95(3):809-52. PubMed ID: 26109340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.